SG11202012344RA - A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof - Google Patents
A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereofInfo
- Publication number
- SG11202012344RA SG11202012344RA SG11202012344RA SG11202012344RA SG11202012344RA SG 11202012344R A SG11202012344R A SG 11202012344RA SG 11202012344R A SG11202012344R A SG 11202012344RA SG 11202012344R A SG11202012344R A SG 11202012344RA SG 11202012344R A SG11202012344R A SG 11202012344RA
- Authority
- SG
- Singapore
- Prior art keywords
- disubstituted
- methods
- pyrazolyl steroid
- steroid
- pyrazolyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684155P | 2018-06-12 | 2018-06-12 | |
| US201962789329P | 2019-01-07 | 2019-01-07 | |
| US201962841645P | 2019-05-01 | 2019-05-01 | |
| PCT/US2019/036848 WO2019241442A1 (en) | 2018-06-12 | 2019-06-12 | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202012344RA true SG11202012344RA (en) | 2021-01-28 |
Family
ID=67211854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202012344RA SG11202012344RA (en) | 2018-06-12 | 2019-06-12 | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20210338692A1 (pt) |
| EP (1) | EP3806863A1 (pt) |
| JP (2) | JP2021527092A (pt) |
| KR (1) | KR20210021005A (pt) |
| CN (2) | CN117959309A (pt) |
| AU (1) | AU2019287491A1 (pt) |
| CA (1) | CA3103421A1 (pt) |
| IL (1) | IL279315A (pt) |
| MA (1) | MA52894A (pt) |
| MX (1) | MX2020013557A (pt) |
| SG (1) | SG11202012344RA (pt) |
| TW (1) | TW202005653A (pt) |
| WO (1) | WO2019241442A1 (pt) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201606063RA (en) | 2012-01-23 | 2016-09-29 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| IL304912A (en) | 2012-08-21 | 2023-10-01 | Sage Therapeutics Inc | Treatment methods for epilepsy and status epilepticus |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| SI3224269T1 (sl) | 2014-11-27 | 2020-10-30 | Sage Therapeutics, Inc. | Sestavki in metode za zdravljenje CNS motenj |
| PE20190915A1 (es) | 2016-08-23 | 2019-06-26 | Sage Therapeutics Inc | Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino |
| WO2019113494A1 (en) | 2017-12-08 | 2019-06-13 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| US20230018765A1 (en) * | 2019-12-05 | 2023-01-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| CN115551514A (zh) | 2020-03-25 | 2022-12-30 | 萨奇治疗股份有限公司 | 用于治疗呼吸系统病症的药物的用途 |
| TW202220667A (zh) * | 2020-07-20 | 2022-06-01 | 美商賽吉醫療公司 | 19-nor-c3,3-二取代-c21-n-吡唑基類固醇之調配物及其使用方法 |
| AU2022238365A1 (en) * | 2021-03-17 | 2023-09-21 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder |
| EP4329770A1 (en) * | 2021-04-29 | 2024-03-06 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression |
| MX2023012728A (es) * | 2021-04-29 | 2023-11-08 | Sage Therapeutics Inc | Esteroide neuroactivo para el tratamiento del trastorno depresivo mayor y la depresion posparto en una mujer lactante. |
| TW202341995A (zh) * | 2022-02-16 | 2023-11-01 | 美商賽吉醫療公司 | 用於治療cns相關病症之神經活性類固醇 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102239541B1 (ko) * | 2013-04-17 | 2021-04-14 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| JOP20200195A1 (ar) * | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| LT3206493T (lt) * | 2014-10-16 | 2020-08-25 | Sage Therapeutics, Inc. | Kompozicijos ir būdai, skirti cns sutrikimams gydyti |
| WO2017156103A1 (en) * | 2016-03-08 | 2017-09-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| PE20190915A1 (es) * | 2016-08-23 | 2019-06-26 | Sage Therapeutics Inc | Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino |
| IL303250A (en) * | 2017-09-07 | 2023-07-01 | Sage Therapeutics Inc | Neuroactive steroids and methods of using them |
-
2019
- 2019-06-12 MA MA052894A patent/MA52894A/fr unknown
- 2019-06-12 CN CN202410051762.8A patent/CN117959309A/zh active Pending
- 2019-06-12 US US17/251,475 patent/US20210338692A1/en active Pending
- 2019-06-12 CN CN201980051843.5A patent/CN112533611A/zh active Pending
- 2019-06-12 CA CA3103421A patent/CA3103421A1/en active Pending
- 2019-06-12 AU AU2019287491A patent/AU2019287491A1/en active Pending
- 2019-06-12 SG SG11202012344RA patent/SG11202012344RA/en unknown
- 2019-06-12 KR KR1020217000726A patent/KR20210021005A/ko not_active Application Discontinuation
- 2019-06-12 TW TW108120367A patent/TW202005653A/zh unknown
- 2019-06-12 MX MX2020013557A patent/MX2020013557A/es unknown
- 2019-06-12 WO PCT/US2019/036848 patent/WO2019241442A1/en unknown
- 2019-06-12 JP JP2020569024A patent/JP2021527092A/ja active Pending
- 2019-06-12 EP EP19737327.7A patent/EP3806863A1/en active Pending
- 2019-12-05 US US16/704,800 patent/US20200113917A1/en not_active Abandoned
-
2020
- 2020-12-09 IL IL279315A patent/IL279315A/en unknown
-
2022
- 2022-06-17 US US17/843,031 patent/US20220323462A1/en active Pending
-
2023
- 2023-12-05 JP JP2023205211A patent/JP2024028849A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3103421A1 (en) | 2019-12-19 |
| AU2019287491A1 (en) | 2021-01-07 |
| WO2019241442A1 (en) | 2019-12-19 |
| MX2020013557A (es) | 2021-05-27 |
| TW202005653A (zh) | 2020-02-01 |
| CN112533611A (zh) | 2021-03-19 |
| JP2024028849A (ja) | 2024-03-05 |
| EP3806863A1 (en) | 2021-04-21 |
| US20200113917A1 (en) | 2020-04-16 |
| US20210338692A1 (en) | 2021-11-04 |
| IL279315A (en) | 2021-01-31 |
| KR20210021005A (ko) | 2021-02-24 |
| MA52894A (fr) | 2021-04-21 |
| US20220323462A1 (en) | 2022-10-13 |
| JP2021527092A (ja) | 2021-10-11 |
| CN117959309A (zh) | 2024-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279315A (en) | 19-NOR C3,3-dimuter C21-N-pyrazolyl steroid and methods of using it | |
| IL273126A (en) | 19-NOR C3,3-dimethyl C21-N-pyrazolyl steroid and methods of using it | |
| IL286794A (en) | 19- nor c3, 3- dimethomer c21- n- pyrazole Steroids and methods of using them | |
| ZA201901051B (en) | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid | |
| IL283629A (en) | Neuroactive steroids and methods of using them | |
| IL275757A (en) | Steroids and always their antibody | |
| IL273099A (en) | Neuroactive steroids and methods of using them | |
| GB201805302D0 (en) | Ensemble Model Creation And Selection | |
| IL299829A (en) | Formulations of 19-NOR C3,3-dimer C21-N-pyrazolyl steroid and methods of using them | |
| EP3798861A4 (en) | BLOCKCHAIN NODES AND TRANSACTION PROCEDURES | |
| EP3739571A4 (en) | VOICE SYNTHESIS PROCESS, VOICE SYNTHESIS DEVICE AND PROGRAM | |
| EP3848861A4 (en) | PLANNING DEVICE, PLANNING PROCEDURE AND PLANNING PROGRAM | |
| EP3834677A4 (en) | DEVICE, PROCESS AND PROGRAM | |
| EP3847183A4 (en) | C19 SCAFFOLDS AND STEROIDS, METHODS OF USE AND PRODUCTION THEREOF | |
| EP3825073A4 (en) | SIMULATION DEVICE, SIMULATION PROGRAM AND SIMULATION METHOD | |
| SG11202107530WA (en) | Steroid compound, and use thereof and preparation method therefor | |
| EP3696811A4 (en) | VOICE ENTRY DEVICE, ASSOCIATED PROCESS AND PROGRAM | |
| EP3754595A4 (en) | DEVICE, PROGRAM AND CALCULATION PROCESS | |
| EP3842808A4 (en) | ADMINISTRATION MANAGEMENT APPARATUS, ADMINISTRATION MANAGEMENT METHOD AND PROGRAM | |
| GB2589260B (en) | Pipe structure and construction method | |
| SG10201908033QA (en) | Tape, tape attaching method, and tape expanding method | |
| EP3839781A4 (en) | CALCULATION DEVICE, METHOD AND PROGRAM | |
| EP3690164A4 (en) | METAL WALL MATERIAL AND WALL CONSTRUCTION PROCESS WITH IT | |
| EP3829537A4 (en) | LOW DOSAGE INTRANASAL DOSAGE FORMS OF AMINOSTEROL AND METHODS OF USE THEREOF | |
| GB202004486D0 (en) | Flushing devices and methods |